Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Traws Pharma, Inc. - Common Stock (NQ:TRAW)

1.385 -0.005 (-0.36%)

Streaming Delayed Price Updated: 10:38 AM EDT, Apr 21, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	28,850
Open	1.400
Bid (Size)	1.380 (200)
Ask (Size)	1.390 (100)
Prev. Close	1.390
Today's Range	1.380 - 1.410
52wk Range	0.9801 - 3.265
Shares Outstanding	5,564,315
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

TRAWS PHARMA INC (NASDAQ:TRAW) Reports 2025 Earnings Beat Amid Dilutive $60M PIPE Financing and FDA Hold ↗

April 15, 2026

Traws Pharma reports 2025 net income but stock falls on dilutive $60M PIPE financing. Focus remains on clinical trials for its influenza and COVID-19 antiviral candidates.

Via Chartmill

Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights

April 15, 2026

From Traws Pharma, Inc.

Via GlobeNewswire

Performance

YTD	+4.1%	+4.1%
1 Month	-37.6%	-37.6%
3 Month	-46.3%	-46.3%
6 Month	-54.9%	-54.9%
1 Year	-21.3%	-21.3%

More News

Traws Pharma Announces Up to $60 Million Private Placement Financing

April 15, 2026

From Traws Pharma, Inc.

Via GlobeNewswire

Top stock movements in today's session. ↗

February 19, 2026

Via Chartmill

TRAW Stock Slides In Volatile Session – What’s The Latest On Its Phase 2 Trial For COVID-19 Treatment? ↗

January 26, 2026

Via Stocktwits

Gapping stocks in Thursday's session ↗

February 19, 2026

Via Chartmill

Stay updated with the stocks that are on the move in today's pre-market session. ↗

February 19, 2026

Via Chartmill

Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

February 19, 2026

From Traws Pharma, Inc.

Via GlobeNewswire

Top movers analysis in the middle of the day on 2026-01-28: top gainers and losers in today's session. ↗

January 28, 2026

Via Chartmill

Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

January 26, 2026

From Traws Pharma, Inc.

Via GlobeNewswire

Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients

January 13, 2026

From Traws Pharma, Inc.

Via GlobeNewswire

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗

December 17, 2025

Via Chartmill

Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients

December 17, 2025

From Traws Pharma, Inc.

Via GlobeNewswire

Top movers analysis one hour before the close of the markets on 2025-11-14: top gainers and losers in today's session. ↗

November 14, 2025

Via Chartmill

Which stocks are moving on Friday? ↗

November 14, 2025

Via Chartmill

12 Health Care Stocks Moving In Friday's Intraday Session ↗

November 14, 2025

Via Benzinga

Traws Pharma Reports Third Quarter 2025 Results and Business Highlights

November 13, 2025

From Traws Pharma, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

October 27, 2025

Via Benzinga

Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025

October 14, 2025

From Traws Pharma, Inc.

Via GlobeNewswire

Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives

October 06, 2025

From Traws Pharma, Inc.

Via GlobeNewswire

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Appoints Mark Guerin as Chief Financial Officer

September 25, 2025

Via Investor Brand Network

Annovis Appoints Mark Guerin as Chief Financial Officer

September 25, 2025

From Annovis Bio Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

September 17, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

September 05, 2025

Via Benzinga

Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025

August 18, 2025

From Traws Pharma, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Traws Pharma, Inc. - Common Stock publicly traded?

Yes, Traws Pharma, Inc. - Common Stock is publicly traded.

What exchange does Traws Pharma, Inc. - Common Stock trade on?

Traws Pharma, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Traws Pharma, Inc. - Common Stock?

The ticker symbol for Traws Pharma, Inc. - Common Stock is TRAW on the Nasdaq Stock Market

What is the current price of Traws Pharma, Inc. - Common Stock?

The current price of Traws Pharma, Inc. - Common Stock is 1.385

When was Traws Pharma, Inc. - Common Stock last traded?

The last trade of Traws Pharma, Inc. - Common Stock was at 04/21/26 10:38 AM ET

What is the market capitalization of Traws Pharma, Inc. - Common Stock?

The market capitalization of Traws Pharma, Inc. - Common Stock is 7.71M

How many shares of Traws Pharma, Inc. - Common Stock are outstanding?

Traws Pharma, Inc. - Common Stock has 8M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.